Exposure-Response Modeling to Support Dosing Selection for Phase IIb Development of Kukoamine B in Sepsis Patients
Open Access
- 19 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Aim: Kukoamine B, a small molecule compound, is being developed for the treatment of sepsis in a Phase II clinical trial. The objective of this study was to optimize dosing selection for a Phase IIb clinical trial using an exposure-response model.Methods: Data of 34 sepsis patients from a Phase IIa clinical trial were used in the model: 10 sepsis patients from the placebo group and a total of 24 sepsis patients from the 0.06 mg/kg, 0.12 mg/kg, and 0.24 mg/kg drug groups. Exposure-response relationship was constructed to model the impact of the standard care therapy and area under curve (AUC) of kukoamine B to the disease biomarker (SOFA score). The model was evaluated by goodness of fit and visual predictive check. The simulation was performed 1,000 times based on the built model.Results: The data of the placebo and the drug groups were pooled and modeled by a nonlinear mixed-effect modeling approach in sepsis. A latent-variable approach in conjunction with an inhibitory indirect response model was used to link the standard care therapy effect and drug exposure to SOFA score. The maximum fraction of the standard care therapy was estimated to 0.792. The eliminate rate constant of the SOFA score was 0.263/day for the standard care therapy. The production rate of SOFA score (Kin) was estimated at 0.0569/day and the AUC at half the maximal drug effect (EAUC50) was estimated at 1,320 h*ng/mL. Model evaluation showed that the built model could well describe the observed SOFA score. Model-based simulations showed that the SOFA score on day 7 decreased to a plateau when AUC increased to 1,500 h*ng/mL.Conclusion: We built an exposure-response model characterizing the pharmacological effect of kukoamine B from the standard care therapy in sepsis patients. A dose regimen of 0.24 mg/kg was finally recommended for the Phase IIb clinical trial of kukoamine B based on modeling and simulation results.Keywords
This publication has 23 references indexed in Scilit:
- Sepsis and septic shockThe Lancet, 2018
- Improvement in latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint in rheumatoid arthritisJournal of Pharmacokinetics and Pharmacodynamics, 2015
- Latent variable indirect response joint modeling of a continuous and a categorical clinical endpointJournal of Pharmacokinetics and Pharmacodynamics, 2014
- Exposure–Response Modeling of Clinical End Points Using Latent Variable Indirect Response ModelsCPT: Pharmacometrics & Systems Pharmacology, 2014
- Cross-validation for nonlinear mixed effects modelsJournal of Pharmacokinetics and Pharmacodynamics, 2013
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Septic shockThe Lancet, 2005
- CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both?Scandinavian Journal of Infectious Diseases, 2003
- Serial Evaluation of the SOFA Score to Predict Outcome in Critically Ill PatientsJAMA, 2001
- Integrated Functions for Four Basic Models of Indirect Pharmacodynamic ResponseJournal of Pharmaceutical Sciences, 1998